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I M M U N O L O G Y
Poly(amino acids) as a potent self-adjuvanting delivery 
system for peptide-based nanovaccines
Mariusz Skwarczynski1*†, Guangzu Zhao1†, Jennifer C. Boer2, Victoria Ozberk3, Armira Azuar1, 
Jazmina Gonzalez Cruz4, Ashwini Kumar Giddam3, Zeinab G. Khalil4, Manisha Pandey3,  
Mohini A. Shibu1, Waleed M. Hussein1, Reshma J. Nevagi1, Michael R. Batzloff3, James W. Wells4, 
Robert J. Capon5, Magdalena Plebanski2, Michael F. Good3, Istvan Toth1,5,6*
To be optimally effective, peptide-based vaccines need to be administered with adjuvants. Many currently available 
adjuvants are toxic, not biodegradable; they invariably invoke adverse reactions, including allergic responses and 
excessive inflammation. A nontoxic, biodegradable, biocompatible, self-adjuvanting vaccine delivery system is 
urgently needed. Herein, we report a potent vaccine delivery system fulfilling the above requirements. A peptide 
antigen was coupled with poly-hydrophobic amino acid sequences serving as self-adjuvanting moieties using 
solid-phase synthesis, to produce fully defined single molecular entities. Under aqueous conditions, these molecules 
self-assembled into distinct nanoparticles and chain-like aggregates. Following subcutaneous immunization in 
mice, these particles successfully induced opsonic epitope-specific antibodies without the need of external adjuvant. 
Mice immunized with entities bearing 15 leucine residues were able to clear bacterial load from target organs 
without triggering the release of soluble inflammatory mediators. Thus, we have developed a well-defined and 
effective self-adjuvanting delivery system for peptide antigens.
INTRODUCTION
Vaccines are one of the most powerful tools to combat infectious 
diseases. Although whole-pathogen and protein-based vaccines are 
able to provide efficient protection against pathogens, they are not 
always entirely safe and may induce undesirable immune responses. 
An obvious alternative are peptide-based vaccines because they can 
be designed to induce specific immune responses against selected 
epitopes (1, 2). For instance, the majority of anticancer vaccines in the 
late-phase clinical trials are composed of peptide antigens (3). All 
recent vaccines against group A Streptococcus (GAS) that have entered 
clinical trials are based on peptides derived from a major GAS viru-
lence factor, M-protein, but do not contain the whole protein itself 
(4). GAS is responsible for a variety of mild infections and life- 
threatening autoimmune diseases such as rheumatic fever and rheu-
matic heart disease (5), which are estimated to kill 1.4 million people 
worldwide per year (6). M-protein is the major antigen responsible 
for triggering these autoimmune responses (7). Nevertheless, it is 
possible to identify M-protein–based peptide antigens that do not 
stimulate an autoimmune response and are conserved among the 
vast number of GAS serotypes. These antigens need to be coad-
ministered with an adjuvant and/or an appropriate delivery system 
to induce an effective immune response. However, there is limited 
choice of safe and efficient adjuvants that can stimulate the desired 
immune response against a peptide epitope (8). In general, alum is 
the only adjuvant widely used for the formulation of commercial 
vaccines. A few other adjuvants have been approved for specific 
vaccine formulations (9). Unfortunately, alum is too weak an adju-
vant to stimulate a strong immune response against peptides. Power-
ful adjuvants, such as the “gold standard” complete Freund’s adjuvant 
(CFA), are effective in triggering recognition of the peptide antigen 
by the immune system. However, they are often toxic and/or are 
poorly chemically defined fragments of bacteria or toxins and vary 
from batch to batch. Adjuvant typically includes mixtures of lipids, 
polysaccharides, polymers, or various microbial components. Vaccines 
with added Toll-like receptor (TLR) stimulators or inflammasome 
activators necessarily induce inflammation to stimulate immunity. 
These vaccines, therefore, intrinsically carry the potential of unwanted 
inflammatory side effects mediated largely by soluble mediators such 
as interleukin-1 (IL-1) or tumor necrosis factor (TNF). These can 
also potentially limit their heterologous (nonspecific) beneficial effects 
(10) and be associated with the downstream induction of immuno-
suppressive control mechanisms (11). Thus, a chemically defined 
single compound/adjuvant that can help stimulate an immune re-
sponse, without triggering the release of soluble mediators of in-
flammation, especially against weakly immunogenic antigens, is in 
high demand.
As nanoparticles have been shown to have promising self-adjuvant-
ing properties (12, 13), amphiphiles that self-assemble into them are 
often used in peptide vaccine delivery (14–16). For example, hydro-
phobic dendritic poly(tert-butyl acrylate) has previously been conju-
gated to a variety of peptide epitopes, including GAS-derived peptides, 
and the conjugates have been self-assembled to form particles (17). 
These particles induced strong humoral and cellular immune responses 
against the incorporated peptide antigen/s without any indication of 
adverse effects (17–19). However, these polymers had serious limita-
tions for commercial application because they are not biodegradable 
and have undefined stereochemistry and number of units in each 
polymer. Although this is typical for classical polymers, the batch-
to-batch variability affects in vitro and in vivo results and makes 
them unsuitable for clinical trial.
Herein, we propose a self-adjuvanting peptide-based vaccine delivery 
system designed to overcome these disadvantages. This system is 
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based on fully defined and biodegradable polymers built from natural 
hydrophobic amino acids (HAAs). In contrast to the often laborious 
methods required for polymer production, especially in dendritic 
forms, poly-HAAs (pHAAs) were synthesized using the classical 
solid-phase peptide synthesis (SPPS) method. This method could 
be fully automated and allowed incorporation of the desired peptide 
epitopes into the molecule in the same procedure. The properties of 
the pHAA unit (e.g., water solubility, conformational behavior) can 
easily be altered by changing its length and amino acid composition. 
We selected three typical HAAs (valine, phenylalanine, and leucine) 
to examine whenever their polymeric arrangement conjugated to a 
peptide epitope could self-assemble into nanoparticles. A conserved 
B cell epitope derived from GAS M-protein (J8, QAEDKVKQSREAK-
KQVEKALKQLEDKVQ), which recently reached phase 1 clinical trials, 
and a universal T helper epitope (PADRE, AKFVAAWTLKAAA) 
were incorporated into the vaccine design and modified with pHAA 
(Fig. 1). The pHAAs were built from valine, phenylalanine, and leucine: 
typical representatives of HAAs. The resulting amphiphilic compounds 
were self-assembled into particles that induced the maturation of 
antigen-presenting cells (APCs) in vitro and the production of high 
antibody titers. Mechanistically, they were able to induce dendritic 
cell (DC) maturation without induction of potentially damaging 
soluble inflammatory mediators in a mouse model. These antibodies 
opsonized clinical GAS isolates in vitro and greatly reduced the bac-
terial burden in mice challenged with the M1 GAS strain.
RESULTS
Synthesis of pHAA-peptide conjugates
The B cell epitope J8 and T helper PADRE were conjugated on resin 
using the standard Boc-SPPS method, with the lysine as a spacer 
and branching moiety for attachment of pHAA, to produce peptide 1 
(Fig. 1). The peptide 1 was modified with 10 U of valine, 10 U of 
phenylalanine, 10 U of leucine, or 15 U of leucine to yield com-
pounds 2, 3, 4, and 5, respectively. pHAAs of these lengths were 
expected to induce conjugate aggregation under aqueous conditions. 
All compounds were acetylated on their N terminus. An attempt to 
synthesize a compound that bore 15 valines was unsuccessful due to 
its high hydrophobicity, aggregative nature, and insolubility, con-
sistent with the properties of previously reported poly-valine sequences 
(20). Similar problems were encountered during the synthesis and 
purification of a 15-phenylalanine derivative. Although the com-
pound that bore 15 leucines precipitated when concentration was 
higher than 1.5 mg/ml, this was still practical for immunological 
evaluation.
Self-assembly and characterization  
of pHAA-peptide nanoparticles
Hydrophilic peptide epitope 1 upon conjugation with hydrophobic 
pHAA sequences forms conjugates (2 to 5). Therefore, 2 to 5 have 
amphiphilic properties and are able to self-assemble to form particles. 
Compounds (2 to 5) were self-assembled in phosphate-buffered 
saline (PBS) and examined by dynamic light scattering (DLS) and 
transmission electron microscopy (TEM). All compounds self- 
assembled into a mixture of small nanoparticles (10 to 30 nm) and 
larger aggregates with high polydispersity indexes according to DLS 
(table S1 and fig. S1) and TEM (Fig. 2, A to D). Distinct nanoparticles 
and chain-like aggregates of nanoparticles (CLAN) are visible in the 
TEM images (Fig. 2), especially for compound 5 (fig. S2).
Secondary structure analysis of the conjugates
The B cell epitope J8 was designed to adopt a helical conformation 
to trigger the production of antibodies that recognize native helical 
GAS M-protein. However, in aqueous solvents, without use of helicity 
inducing 2,2,2-trifluoroethanol, it adopted a random coil conforma-
tion rather than an  helix. Therefore, circular dichroism (CD) was 
used to test whether the J8-PADRE (1) epitope alone or after conju-
gation with pHAAs was able to adopt a helical conformation in PBS 
(Fig. 2E). As expected, the CD spectra of peptide 1 suggested the 
presence of a mixture of random coil (with typical minimum at 202 nm) 
and  helix (flat minimum at 222 nm). Only conjugate 5 adopted a 
typical helical conformation with a clear minimum at 223 nm and a 
lower-intensity minimum at 209 nm. Its analog bore a shorter leucine- 
repeat unit (4) and had a clear minimum at 207 nm and weaker at 
221 nm. Compound 2 bore 10 valines and appeared as a mixture of 
an  helix and a  sheet with a flat minimum between 205 and 221 nm, 
which most likely have resulted from overlapping of  helix mini-
mums at 208 and 222 nm, with a  sheet minimum at 215 nm. The 
tendency of valine-rich peptides to form  sheets is well documented 
(21). The CD spectrum of compound 3 displayed an unusual single 
minimum ellipticity at 222 nm, which was neither typical of an  helix 
nor a  sheet. However, this type of CD spectra has been observed 
for  sheet–rich proteins (22, 23).
Cytotoxicity of the conjugates 2 to 5
The vaccine delivery system/adjuvant was constructed entirely 
from natural amino acids; thus, the pHAA conjugates were not 
expected to be toxic. None of the compounds showed any cyto-
toxicity against SW620 (human colon carcinoma) and human em-
bryonic kidney (HEK) 293 cell lines at the highest tested concentration 
(30 M).
Fig. 1. Schematic structures of compounds 1 to 5. The vaccine candidates were 
constructed from three building blocks: the B cell epitope (J8), the T helper epitope 
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Ability of conjugates to stimulate the maturation of DCs, 
macrophages, and cellular responses
Maturation of APCs (CD11c + DCs and F4/80+ macrophages from 
murine splenocytes) was determined after their treatment with 2 to 5 
by analyzing the expression of major histocompatibility complex II 
(MHC-II) and the CD40 costimulatory molecule in vitro (fig. S3). 
All conjugates induced higher expression of MHC-II compared with 
negative control, while only compound 5 induced significantly higher 
expression of CD40 in both DCs and macrophages (P = 0.011 and 
0.0027, respectively). In the second experiment, long-term stimula-
tion of macrophages and DCs was evaluated in vivo. Following two 
immunizations, spleens were collected 17 days after the final immuniza-
tion. Maturation of APCs (CD11c + DCs and F4/80+ macrophages 
from murine splenocytes) was determined after their treatment with 
5 and adjuvanted controls 1/AS04 [alum and monophosphoryl lipid A 
(MPLA) containing human-grade adjuvant]. Compound 5 stimu-
lated significantly higher expression of CD40 and CD86 on DCs. 
1/AS04 did not stimulate significant increases, albeit similar trends 
were observed. These makers were not significantly higher on macro-
phages compared with negative controls (PBS) by any adjuvant (fig. S4). 
Similar results were observed in inguinal lymph nodes, which were the 
lymph nodes draining the injection sites (data not shown). The endo-
toxin level in the vaccine formulation 5 was negligible (0.0044 EU/ml) 
and therefore could not influence the compound ability to stimulate 
DCs. In addition, to assess the immunogenicity of 5 in comparison 
to adjuvant control 1/AS04, we also measured cytokine-producing 
T cell responses from whole splenocytes by enzyme-linked immuno-
sorbent spot (ELISpot; fig. S5). There were significant T helper 1 cell 
(TH1) responses observed in a number of animals after just two im-
munizations with the control adjuvant 1/AS04 recalled with 5 (none 
of six animals responding), 1 (one of six), or PADRE (three of six) 
with a similar pattern, albeit at lower overall levels, observed for 
compound 5 recalled with 5 (none of six), 1 (one of six), or PADRE 
(two of six). In terms of TH2 responses 1/AS04, there were only signifi-
cant responses to 5 or 1 in one of six animals with a similar pattern 
for compound 5, with reactivity to 5 found in one of six animals, to 
1 in one of six animals, and to PADRE in one of six animals. There 
was no TH17 reactivity induced by either 1/AS04 or compound 5 to 
any recall antigen in the culture. Together, these data show that 
compound 5 can induce early modest TH1 and TH2 reactivity com-
parable to 1/AS04.
Systemic and mucosal immune responses induced by 
compounds 2 to 5
C57BL/6 female mice received tail base subcutaneous immunization 
and three boosts with compounds 2 to 5 on days 0, 21, 28, and 35. 
All compounds elicited significant J8-specific immunoglobulin G (IgG) 
titers after the final immunization (Fig. 3A). Compound 5 induced 
significantly stronger responses than all other compounds, including 
1 emulsified with CFA (P = 0.0219). While compound 5 induced 
significant antibody titers since the first immunization, one boost 
with compound 5 was not enough to induce production of antibody 
titters higher than that induced by oil-based adjuvants AS04 and CFA 
(fig. S6). However, two of the CFA-immunized mice died, illustrating 
the known concerns with toxicity associated with this gold standard 
adjuvant.
The ability of compounds 1 to 5 to induce mucosal immune 
responses after subcutaneous immunization was also examined. 
Conjugates 2 and 5 and peptide 1 emulsified with CFA induced 
production of J8-specific IgA in mice (Fig. 3B). The IgA titers were 
relatively low, yet significantly higher than those observed in mice 
treated with PBS. Similarly, the salivary IgG titers induced by im-
munization with the conjugates (Fig. 3C) were very low (2), low 
(3 and 4), or moderate (1/CFA), with the exception of compound 5, 
which induced significantly higher (P < 0.0001) salivary IgG pro-
duction than the positive control group (1/CFA).
The quality of these antibodies was tested in opsonization assays 
against a variety of GAS clinical isolates (Fig. 3, D to I). Sera collected 
from mice immunized with compounds that bore leucine-based pHAA 
units (4 and 5) and 1/CFA induced high levels of opsonization of all 
GAS strains when compared with sera derived from the mice treated 
with PBS. In particular, the sera collected from mice immunized with 
compound 5 demonstrated, in most cases, significantly better ability 
to kill bacteria than that from other groups (Fig. 3, D to I), including 
1/CFA (Fig. 3I). Compound 4, which was less potent than 5, still 
generated better opsonic responses than 2 or 3.
Fig. 2. Physicochemical characterization of compounds 1 to 5. TEM photographs 
of the vaccine compounds (A) 2, (B) 3, (C) 4, and (D) 5 (scale bars, 200 nm). (E) Circular 
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Postimmunization intranasal challenge with M1 GAS
Following intranasal bacterial challenge, the number of bacteria was 
measured using nasal shedding, throat swabs, and the colonization 
of nasal-associated lymphoid tissue (NALT; a murine functional 
homolog to human tonsils) and the spleen (Fig. 4). Both nasal shed-
ding and throat swabs were analyzed at days 1 to 3. In both mucosal 
areas, compound 5 demonstrated the highest efficacy for clearing 
GAS bacteria, which, by day 3, were practically undetectable in mice 
immunized with this conjugate (Fig. 4, A and B). The NALT and 
spleen tissue gave similar results to the mucosal surfaces: by day 3, 
5 induced the strongest reduction of bacterial burden of any tested 
compound, including CFA-adjuvanted peptide 1.
Inflammatory responses
Activation of the inflammasome NLRP3 leads to autocatalytic caspase-1 
activation, which, in turn, cleaves the pro-cytokines IL-1 and IL-18. 
Cleavage induces maturation of IL-1 and IL-18 into soluble and 
biologically active cytokines. Aside from lipopolysaccharide (LPS), 
silica are also well-known inflammasome activators (24). Previous 
studies have shown that prestimulation of LPS followed by silica 
triggered the maturation of NLRP3 inflammasome and, conse-
quently, the cleavage of pro–IL-1 into active IL-1 in the immor-
talized bone marrow–derived macrophages (BMMs) (25). Prestimu-
lating BMMs with LPS followed by silica stimulated the production 
of IL-1 (729 ± 509 pg/ml; Fig. 5A). However, prestimulation of 
LPS followed by compound 5 or 1 and either of the compounds 
alone did not trigger the release of IL-1, further suggesting that 
compounds 5 and 1 do not induce the maturation and assembly of 
the inflammasome complex and are therefore noninflammatory.
In addition, we analyzed the expression of TNF, a well-known 
inflammatory cytokine. When BMMs were stimulated with either 
LPS, 5, or control peptide 1, cells exhibited no differences in TNF 
production in comparison with untreated cells (Fig. 5B).
DISCUSSION
Adjuvants play a key role in modern vaccines (26). Despite some 
safety concerns, many currently available adjuvants are not fully 
defined and may include mixtures of lipids, polysaccharides, polymers, 
and various microbial components. Thus, a chemically defined single 
compound that can help stimulate an immune response against the 
antigen it carries would have clear benefits over many existing adjuvants. 
As nanoparticles have been shown to have promising self-adjuvanting 
properties (12), amphiphiles that self-assemble into nanoparticles are 
Fig. 3. J8-specific antibody titer and average opsonization percentage of different GAS strains. Experimental mice (C57BL/6, n = 10) were vaccinated subcutaneously 
(on days 0, 21, 28, and 35) with compounds 1 to 5. Each triangle in (A) to (C) represents an individual mouse; the mean J8-specific titers are presented as a bar. (A) Titers 
of J8-specific immunoglobulin G (IgG) in serum, (B) titers of J8-specific IgA in saliva, and (C) titers of J8-specific IgG in saliva, collected after final immunization. (D) Average 
percentage opsonization of GAS strain 2002, (E) D2612, (F) D3840, (G) GC2 203, (H) 5203, and (I) 5199. PBS: negative control group, mice immunized with PBS; 1/CFA: 
positive control group, compound 1 emulsified with CFA. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test 
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often used in peptide vaccine delivery (14, 15). Herein, we propose a 
universal peptide-based platform (pHAA), which upon conjugation 
to an anti gen stimulates formation of nanoparticles. The properties 
of pHAA unit (e.g., water solubility and conformational) can easily 
be altered by changing its length and amino acid composition. We 
selected three HAAs (valine, phenylalanine, and leucine) to examine 
whether their polymeric arrangement conjugated to a peptide epitope 
could self-assemble into nanoparticles. GAS B cell epitope J8 con-
jugated to universal T helper epitope PADRE (1) was selected as a 
vaccine antigen and modified with 10 or 15 copies of HAA (Fig. 1). 
pHAAs of these lengths were expected to induce conjugate aggrega-
tion under aqueous conditions. Compounds that bore 15 repeats of 
phenylalanine and valine were poorly water soluble and were there-
fore discontinued from further studies. Although the compound 
that bore 15 leucines precipitated when concentration was higher than 
1.5 mg/ml, this was still practical for immunological evaluation. Thus, 
the maximum length of pHAA sequence, which could be used to 
deliver peptide antigens, was essentially limited by the compounds’ 
aqueous solubility. Other compounds were easily water soluble; 
however, as they have amphiphilic properties due to the presence of 
highly hydrophobic pHAA units and hydrophilic peptide antigen (1), 
they promptly self-assembled under aqueous conditions. All of them 
(2 to 5) formed small nanoparticles and CLAN. Similar aggregates 
were previously reported for inorganic nanoparticles (27, 28). The 
aggregative potential of all compounds was generally similar with 
the exception of compound 5, which had a higher tendency to form 
CLAN (Fig. 2, A to D, table S1, and fig. S2). This can easily be 
Fig. 4. Bacterial burden after intranasal challenge with M1 GAS strain in C57BL/6 mice (n = 10 per group). Bacterial burden results are represented as the mean 
CFU ± SEM for each group. (A) Nasal shedding, (B) throat swabs, (C) colonization of nasal-associated lymphoid tissue (NALT), and (D) colonization of spleen tissue. PBS: 
negative control group, mice immunized with PBS; 1/CFA: positive control group, compound 1 emulsified with CFA. On day 1, 10 mice were examined; on day 2, 5 mice 
were examined and euthanized for spleen and NALT organ harvesting; and the remaining 5 mice were processed on day 3. Statistical analysis was performed using a 
two-way ANOVA followed by Tukey’s post hoc test compared with PBS indicated as ns, P > 0.05; *P < 0.05; **P < 0.01; ****P < 0.0001.
Fig. 5. Cytokine production following stimulation with 5 and 1 with or with-
out costimulation of LPS. Cytokine production is expressed as pg/mL ± SD. 
(A) Production of IL-1 stimulated by LPS (0.1 g/ml), silica (125 g/ml), peptide 1 
(0.1 mg/ml), and compound 5 (0.1 mg/ml). (B) Production of TNF stimulated by 
LPS (0.001 g/ml), peptide 1 (0.1 mg/ml), and compound 5 (0.1 mg/ml). Positive 
control: cells stimulated with LPS alone or in combination with silica. Negative 
control: untreated cells. Cells were prestimulated with LPS for 3 hours followed by 
either 6 hours of stimulation with silica or 4 hours of stimulation with 5 and control 
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explained by its more hydrophobic nature. The same compound 
adopted the most distinct secondary structure. A classical double- 
minimum  helix CD spectrum was observed for 5, while the spectra 
of its shorter analog 4 and peptide antigen 1 showed a shift of the 
helical curve toward random coil (Fig. 2E). In contrast, compounds 
2 and 3 rather showed a tendency to form a  sheet. The antibodies 
induced against the J8 epitope need to recognize the parent helical 
M-protein; thus, the conformational properties of the vaccine have 
an important role in its antibacterial efficacy. It has been also recently 
reported that modification of p145 (LRRDLDASREAKKQVEKALE), 
the parent peptide of J8 that share same minimal B cell epitope 
(SREAKKQVEKAL), which stabilized helical folding, greatly induced 
its immunogenicity (29). Following immunization with 5, antibodies 
generated by mice showed the strongest ability to opsonize GAS clinical 
isolates in vitro (Fig. 4). At the same time,  sheet–rich compounds 
2 and 3 appeared to induce production of nonprotective antibodies 
that were not able to kill GAS bacteria. Compound 5 also demonstrated 
excellent ability to protect mice in the M1 GAS challenge experiment 
(Fig. 5). Clearance of GAS bacteria was not observed in mice immunized 
with 4, which suggested that not only the opsonic ability but also the 
quantity of antibodies played an important role in protection. Com-
pound 5 induced significantly higher J8-specific systemic and mucosal 
IgG titers than the other compounds. Relatively, low IgA titers were 
observed (as expected) after nonmucosal immunization, and there-
fore, the level of IgA production was not influential on the vaccine 
performance of the candidates. As antigen presentation and matura-
tion of APCs are important for induction of effective humoral im-
munity, expression of MHC-II and CD40 was examined. MHC-II is an 
APC receptor required for peptide antigen presentation to T helper 
cells and, therefore, the induction of adaptive immunity, while the 
level of CD40 expression is typically used as a marker for DC matura-
tion in mice. As expected, all compounds stimulated overexpression of 
both proteins. However, statistically significant overexpression of CD40 
was observed only in mice treated with compound 5. When matura-
tion was examined in vivo, a similar tendency was observed, even 
17 days after stimulation of DCs, with compound 5 (fig. S4). Thus, 
compound 5 demonstrated the most promising properties among 
all examined pHAA-based immunogens. However, the mechanism 
of action (including DC maturation) for the adjuvanticity of nano-
particles, when these do not carry ligands for pattern recognition 
receptors, is still highly speculative (30, 31).
While the quality of the immune response elicited by compound 
5 can be explained by its ability to adopt helical conformation due 
to the presence of a poly-leucine unit, the magnitude of response 
(e.g., high antibody titers) could not be explained by the conformation 
of the epitope and instead resulted from the higher hydrophobicity 
of the compound. When the same size and charge gold nanoparticles 
were examined, those modified with more hydrophobic groups in-
duced stronger immune system activation (32). The hydrophobic 
properties and conformation can easily be modified by changing 
the type and number of amino acids in the pHAA unit, and therefore, 
the system can easily be customized for different epitopes. Moreover, 
in comparison to many other self-assembling systems, an external 
adjuvant was not needed to trigger a strong immune response (33).
Inflammation is one of the common side effects associated with 
the use of most vaccine adjuvants (30). For example, the commonly 
licensed adjuvant alum specifically activates the NLRP3 inflammasome, 
whereas other adjuvants in more restricted use, such as MPLA in 
Cervarix, activate inflammation via the TLR4 receptor. Undesirable 
side effects, such as toxicity, can be associated with the induction of 
excessive inflammatory responses (34). Moreover, inflammatory 
adjuvanted vaccines may lack the capacity to induce beneficial non-
specific systemic effects on immunity, which can be induced by 
some live vaccines (10, 35). Thus, to further analyze the safety of 5 
and to gain mechanistic insight in the function of the nanoparticles, 
we examined the production of inflammatory cytokines associated 
with the presence of TLR or NLRP3 inflammasome activation. Inflam-
masomes are cytosolic molecular complexes involved in pathogen 
recognition and danger. The best characterized inflammasome is 
NLRP3, of which the assembly is associated with the production of 
IL-1 and IL-18 (36). Stimulation via TLR receptors, including the 
TLR4 receptor, activates the production of TNF (30), a well-known 
inflammatory cytokine. Under physiological conditions, during host 
invasion, the conserved structural elements of pathogens including 
LPS bind to TLRs and induce the secretion of TNF, which, in turn, 
exerts its antipathogen response by activating effector T cells (37, 38). 
Overall, TNF has a vast array of complex functions, of which some 
are not yet completely understood; recent studies have even showed 
that oligomerization of the NLRP3 inflammasome may be tran-
scriptionally regulated by TNF (39).
When examined in vitro, no increased production of IL-1 and 
TNF was observed following BMM stimulation with compounds 5 
and control 1 in comparison with untreated cells (Fig. 5). Cells ex-
hibited a very high production of TNF when stimulated with LPS, 
indicating the readily available inflammatory responses of our model. 
These results suggest that the peptides are not triggering the NLRP3 
complex assembly or the conventional TLR signaling pathways of 
these cells and, therefore, not inducing the production of inflammatory 
cytokines. These results support the contention that it is possible to 
induce high levels of immunity without the induction of the full 
spectrum of conventional inflammatory responses, initially described 
using model polystyrene nanoparticles (30), showing successful 
translation of this model concept into an approach with high trans-
lation potential.
The discovery of safe, biocompatible, and immunologically effi-
cient adjuvants is a daunting challenge, with the vast majority of 
known adjuvants composed of microbiological components or their 
synthetic analogs. Here, we demonstrate that conjugating antigens 
to unnatural polymers constructed from natural HAAs leads to self- 
adjuvanting particles. This pHAA-based antigen delivery system 
can be fully customized, for example, to achieve desired aqueous 
solubility and particle formation characteristics of conjugates. This 
breakthrough opens the door for the discovery of safer, better, 
next-generation adjuvants that can lead to a revolution in the field 
of vaccine development.
MATERIALS AND METHODS
Reagents, cells, and equipment
All chemicals were used as received, without any purification. Butyloxy-
carbonyl (Boc)–protected l-amino acids were purchased from Novabio-
chem (Merck Chemicals, Darmstadt, Germany) and Mimotopes 
(Melbourne, Australia); methanol, trifluoroacetic acid (TFA), N,N′- 
diisopropylethylamine (DIPEA), N,N′-dimethylformamide, acetonitrile, 
and dichloromethane were purchased from Merck (Hohenbrunn, 
Germany); 4-methylbenzhydrylamine (pMBHA) resin was pur-
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(HATU) was purchased from Mimotopes (Melbourne, Australia); 
and p-cresol was obtained from Merck Millipore (Bayswater, Australia). 
AS04 adjuvant (MPLA-SM VacciGrade), complete Freund’s adju-
vant, and goat anti-mouse IgG (H + L)–HRP (horseradish peroxidase) 
(IgG-HRP) conjugate were purchased from Millipore (Temecula, 
California, USA); goat anti-mouse IgA was obtained from InvivoGen 
(San Diego, USA), and analytical-grade Tween 20, (tris-hydroxymethyl)
aminomethane, and glycine were acquired from VWR International 
(Queensland, Australia). Phenol-free Iscove’s Modified Dulbecco’s 
Medium (IMDM) Glutamax medium was purchased from Gibco 
(California, USA). Pierce Chromogenic Endotoxin Quant Kit, 
Streptex Latex Agglutination Test kit, and phenylmethylsulfonyl 
fluoride were purchased from Thermo Scientific (Victoria, Australia). 
Phycoerythrin (PE)/CY7 anti-mouse CD11C was purchased from 
eBioscience (California, USA), and BV421 anti- mouse MHC-II, 
fluorescein isothiocyanate (FITC) anti-mouse CD40, and BV605 
anti-mouse F4/80 were purchased from BioLegend (California, 
USA). Fc-block was obtained from eBioscience (California, USA). 
Yeast extract was purchased from Merck Chemicals (Darmstadt, 
Germany). Todd-Hewitt broth (THB) was purchased from Oxoid 
(Thermo Fisher Scientific, South Australia, Australia), and horse blood 
was obtained from Serum Australis. C57BL/6 mice were purchased 
from the Animal Resources Centre (Western Australia, Australia). 
GAS strains 5448AP used in the GAS intranasal challenge were ob-
tained from M. Walker (University Queensland). GAS strain ACM-
2002 was obtained from Royal Brisbane and Women’s Hospital 
(human abscess–lymph gland), ACM-5199 [American Type Culture 
Collection (ATCC) 12344, National Center for Biotechnology In-
formation (NCIB) 11841, scarlet fever], ACM-5203 (ATCC 19615, 
pharynx of child after a sore throat), GC2 203 (wound swab), D3840 
(nasopharynx swabs), and D2612 (nasopharynx swabs). Enzyme- 
linked immunosorbent assay (ELISA) kits for TNF and IL-1b were 
purchased from Becton Dickinson and BioLegend, respectively. Silica 
(U.S. silica) and all other chemicals were purchased from Sigma- Aldrich 
(Victoria, Australia). Analytical reversed-phase high- performance 
liquid chromatography (RP-HPLC) was performed on a Shimadzu 
(Kyoto, Japan) instrument with 1 ml/min flow rate with compound 
detection at 214 nm. Preparative RP-HPLC was performed using 
Shimadzu (Kyoto, Japan) instrumentation (either LC-20AT, SIL-10A, 
CBM-20A, SPD-20AV, FRC-10A or LC-20AP ×2, CBM-20A, SPD-
20A, FRC-10A) in linear gradient mode. The flow rate was 10 or 
20 ml/min, and the compounds were detected at 230 nm. Separa-
tions were achieved with solvent A (100% H2O and 0.1% TFA) and 
solvent B (90% acetonitrile, 10% H2O, and 0.1% TFA) on a Vydac 
214TP1022 preparative column (C4, 10 m, 22 mm by 250 mm). A 
Perkin-Elmer-Sciex API3000 instrument with Analyst 1.4 software 
(Applied Biosystems/MDS Sciex, Toronto, Canada) was used for 
electrospray ionization mass spectrometry (ESI-MS). Particle size 
and morphology were analyzed by DLS using a Nanosizer (Zetasizer 
Nano Series ZS, Malvern Instruments, UK) with disposable capillary 
cuvettes using Dispersion Technology Software (Malvern Instruments, 
UK) and by TEM using a JEM-1010 microscope (JEOL Ltd., Japan). 
The secondary structure of compounds 1 to 5 was analyzed by a CD 
instrument (Jasco J710 spectropolarimeter, JASCO, Japan) with a 
1-mm cell (Starna) at room temperature. The optical density (OD) 
of the endotoxin assay plate was measured using a Spectramax micro-
plate reader (Molecular Devices, USA) at 405 nm. The absorbance 
of each well in cytotoxicity analysis was measured at 580 nm with a 
PowerWave XS Microplate Reader from Bio-Tek Instruments Inc. 
(Winooski, Vermont). An LSR II flow cytometry instrument (LSR 
II Flow cytometer, BD Biosciences, California, USA) was applied in 
the APC maturation study. An RS-VA 10 vortex mixer (Phoenix 
Instrument, Germany) was used to prepare vaccination solution. 
ELISA plates were analyzed in a Victor3 1420 multilabel counter 
(Perkin Elmer Life and Analytical Sciences, Shelton, USA) and a 
Multiskan Go (Thermo Scientific). ELISpot assay was performed 
with multiscreen 96-well plates (MSIPS4510, Millipore). Plates were 
coated with anti-mouse interferon- (IFN-; AN18, Mabtech), anti- 
mouse IL-4 (BVD4-1d11, BD Biosciences), or IL-17A (Mabtech), 
detected with anti-mouse IFN-–biotin (R4-6A2, Mabtech), anti- 
mouse IL-4–biotin (BVD6-24G2, Mabtech or BD Biosciences), or 
anti-mouse IL-17A–biotin (BD Biosciences) and streptavidin-alkaline 
phosphatase (ALP) or ExtrAvidin-ALP. Last, plates were developed with 
an AP colorimetric kit (Bio-Rad), and pots were counted using an AID 
ELISpot Reader system (AutoImmune Diagnostika, GmbH, Germany).
Synthesis and purification of pHAA-peptide conjugates
Peptides 1 to 5 (Fig. 1) were synthesized by microwave-assisted 
standard Boc-SPPS method. Briefly, deprotection of the Boc group 
was performed twice (1× 2 min and 1× 3 min) with neat TFA, and 
double coupling of amino acids was applied (1× 5 min and 1× 10 min, 
20 W, 70°C). Amino acids were activated by DIPEA and HATU. Peptides 
were cleaved by anhydrous hydrogen fluoride with addition of p-cresol 
as a scavenger. Compounds 1 to 5 were purified by RP-HPLC.
Compound 1. Yield: 34%. Molecular weight: 4823.63. ESI-MS 
[M + 3H]3+ m/z 1608.6 (calc. 1608.9), [M + 4H]4+ m/z 1206.8 (calc. 
1206.9), [M + 5H]5+ m/z 965.8 (calc. 965.7), [M + 6H]6+ m/z 804.9 
(calc. 804.9), [M + 7H]7+ m/z 690.1 (calc. 690.1), [M + 8H]8+ m/z 
603.9 (calc. 604.0), [M + 9H]9+ m/z 537.0 (calc. 537.0). tR = 19.1 min 
(0 to 100% solvent B; C4 column); purity ≥ 99%.
Compound 2. Yield: 23%. Molecular weight: 5814.96. ESI-MS 
[M + 3H]3+ m/z 1938.6 (calc. 1939.3), [M + 4H]4+ m/z 1455.0 (calc. 1454.7), 
[M + 5H]5+ m/z 1164.0 (calc. 1164.0), [M + 6H]6+ m/z 969.9 (calc. 970.1), 
[M + 7H]7+ m/z 831.5 (calc. 831.7), [M + 8H]8+ m/z 728.0 (calc. 727.9). 
tR = 24.1 min (0 to 100% solvent B; C4 column); purity ≥ 99%.
Compound 3. Yield: 28%. Molecular weight: 6295.40. ESI-MS 
[M + 4H]4+ m/z 1574.7 (calc. 1574.9), [M + 5H]5+ m/z 1260.0 (calc. 1260.0), 
[M + 6H]6+ m/z 1050.3 (calc. 1050.2), [M + 7H]7+ m/z 900.4 (calc. 900.3), 
[M + 8H]8+ m/z 788.0 (calc. 787.9), [M + 9H]9+ m/z 700.7 (calc. 700.5). 
tR = 24.5 min (0 to 100% solvent B; C4 column); purity ≥ 99%.
Compound 4. Yield: 28%. Molecular weight: 5955.23. ESI-MS 
[M + 3H]3+ m/z 1985.2 (calc. 1986.1), [M + 4H]4+ m/z 1489.6 (calc. 1489.8), 
[M + 5H]5+ m/z 1192.0 (calc. 1192.0), [M + 6H]6+ m/z 993.5 (calc. 993.5), 
[M + 7H]7+ m/z 851.8 (calc. 851.7), [M + 8H]8+ m/z 745.4 (calc. 745.4). 
tR = 25.6 min (0 to 100% solvent B; C4 column); purity ≥ 99%.
Compound 5. Yield: 26%. Molecular weight: 6521.03. ESI-MS 
[M + 4H]4+ m/z 1631.8 (calc. 1631.3), [M + 5H]5+ m/z 1305.6 (calc. 1305.2), 
[M + 6H]6+ m/z 1088.0 (calc. 1087.8), [M + 7H]7+ m/z 932.9 (calc. 932.6), 
[M + 8H]8+ m/z 816.3 (calc. 816.1), [M + 9H]9+ m/z 725.6 (calc. 725.6). 
tR = 30.9 min (0 to 100% solvent B; C4 column); purity ≥ 99%.
Particle size measurements
Compounds 2 to 5 were self-assembled in PBS to prepare solutions 
(0.5 mg/ml). Then, the average particle sizes (nanometer) of the 
nanostructures were measured by DLS at 25°C. Sizes were analyzed 
using a noninvasive backscatter method, and measurements were taken 
with a 173° scattering angle. Correlation times were based on 10 s 
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Each measurement was repeated five times. The same compound 
solutions were also analyzed by TEM.
Secondary structure analyses
The secondary structure of compounds 1 to 5 (0.1 mg/ml in PBS) was 
analyzed by CD. Spectra were tested with the following parameters: 
5-nm bandwidth; scan rate, 50 nm/min; response time, 2 s; and 1-nm 
intervals over the wavelength range of 195 to 260 nm in a nitrogen 
atmosphere. Reported data are the mean of six accumulations. Mean 
residue molar ellipticity (deg∙cm2∙dmol−1) was calculated using the 
formula [] = mdeg/(l × c × n) * 1000, where l is the path length (0.1 cm), 
c is the peptide concentration (millimolar), and n is the number of 
residues in the peptide.
Endotoxin assay
The assay was performed as per the manufacturer’s instruction. Low 
concentration of lyophilized endotoxin (0.01 to 0.1 EU/ml) was used 
for the preparation of the standard curve (average blank-corrected 
OD at 405 nm versus endotoxin concentration) to determine the 
endotoxin concentration in compound 5 (1 mg/ml in PBS).
Ethics statement
All animal protocols were approved by the Griffith University Animal 
Ethics Committee, GU ref. no. GLY/07/14 and The University of 
Queensland Animal Ethics Committee (AEC), AEC approval no. 
SCMB/AIBN/069/17. This study was carried out in accordance with 
the National Health and Medical Research Council (NHMRC) of 
Australia guidelines for generating, breeding, caring for, and using 
genetically modified and cloned animals for scientific purposes (2007). 
Methods were chosen to minimize pain and distress to the mice, 
which were observed daily by trained animal care staff. The mice 
were terminated using a CO2 inhalation chamber.
Cytotoxicity results study
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) cytotoxicity assay was performed using SW620 and HEK293 
adherent cell lines. SW620 and HEK293 were cultured in RPMI 1640 
medium and Dulbecco’s modified Eagle’s medium (DMEM), respec-
tively, as adherent monolayers in flasks supplemented with 10% fetal 
bovine serum (FBS), 2 mM l-glutamine, penicillin (100 U/ml), and 
streptomycin (100 g/ml) in a humidified 37°C incubator supplied with 
5% CO2. Cells were then harvested with trypsin and dispensed into 96-
well microtiter assay plates at 2000 cells per well for the two cell lines 
and incubated for 18 hours at 37°C with 5% CO2 (to allow cells to at-
tach). Compounds 2 to 5 were dissolved in 5% dimethyl sulfoxide 
(DMSO) in PBS (v/v), and aliquots (10 l) were tested over a series of 
final concentrations ranging from 10 nM to 30 M. Control wells were 
treated with 5% aqueous DMSO. After a 68-hour incubation at 37°C 
with 5% CO2, an aliquot (10 l) of MTT in PBS (5 mg/ml) was added to 
each well (final concentration of 0.5 mg/ml), and the microtiter plates 
were incubated for a further 4 hours at 37°C with 5% CO2. After this 
final incubation, the medium was aspirated and precipitated formazan 
crystals were dissolved in DMSO (100 l per well). The absorbance of 
each well was then measured. Vinblastine was used as a positive control 
(20 mg/ml in H2O). All experiments were performed in duplicate.
APC maturation evaluation
Single-cell spleen suspensions were harvested from naive C57BL/6 
mice by physical disruption of their spleens and passing the disrupted 
spleens through stainless steel mesh. Red blood cell lysis buffer was 
used to lyse the erythrocytes. Then, a 96-well plate was filled with 
2 × 105 cells per well in phenol-free IMDM Glutamax medium sup-
plemented with 10% FBS, 50 mM 2-mercaptoethanol, penicillin 
(100 U/ml), and streptomycin (100 mg/ml). For each well of the 
plates, 10 M of compounds 2 to 5 was added, and the plates were 
incubated at 37°C for 6 hours. Cells that adhered to the wells were 
scraped first, and then Fc-block was added. Following this, the plates 
were put in an incubator for 30 min at 4°C. The cells were centri-
fuged and resuspended in a buffer containing CD11c, F4/80, CD40, 
CD80, and MHC-II antibodies for 30 min at 4°C. After the incuba-
tion, the plates were centrifuged and washed again. The cells were 
then resuspended in 0.5 ml of fluorescence-activated cell sorting 
(FACS) buffer (PBS, 0.02% sodium azide, 0.5% bovine serum albumin). 
The mean fluorescence intensity for CD11C or F4/80 cells and activa-
tion markers CD40 and MHC-II was used to identify the maturation 
of DCs or macrophages.
Vaccination and bacterial infection challenge
C57BL/6 female mice received a primary immunization and three 
boosts with compounds 2 to 5 on days 0, 21, 28, and 35. The com-
pounds 2 to 5/PBS solutions and compound 1/CFA emulsion (1:1 
volume ratio) were prepared fresh before each immunization. 
Compounds 2 to 5 were dissolved in PBS directly and then vortexed 
for 2 min. Mice in each group (10 mice per group) were immunized 
subcutaneously at the base of their tails with 150 g of compound in 
50 to 100 l of PBS.
All immunized and control mice were challenged intranasally 
with the GAS strain M1, with a predetermined dose on the 61st day 
after the primary immunization. The throat swab was obtained on 
days 1 to 3 after the mice were challenged with the GAS bacteria. All 
throat swabs were streaked on Columbia base agar plates containing 
2% defibrinated horse blood incubated at 37°C overnight. The plates 
were stored in a 4°C room for later determination of GAS colonization. 
Nasal shedding was determined on days 1 to 3 after challenge by 
pressing the nares of each mouse onto the surface of the prepared 
Columbia blood agar (CBA) plates 10 times (triplicate CBA plates 
per mouse per day), and exhaled particles were streaked out. On 
days 2 and 3 after challenge, five mice from each group were euthanized 
to harvest the NALT and spleen. The NALT and spleen samples 
were homogenized in PBS first and then plated in serial dilutions on 
Columbia base agar plates containing 2% defibrinated horse blood 
(37°C, overnight) to assess bacterial burden.
In the second vaccination experiment, C57BL/6 female mice re-
ceived a primary immunization and one boost with compound 5 
and the controls on days 0 and 14. The compound 5 solutions (150 g 
of compound 5 in 100 l of PBS) and compound 1/AS04 emulsion 
(5 g of MPLA-SM/5 l of DMSO mixed with 150 g of compound 
1/45 l of PBS according to the manufacturer MPLA-SM VacciGrade’s 
instruction) were prepared freshly before each immunization. Com-
pound 5 was dissolved in PBS directly and then vortexed for 2 min. 
Mice in each group (six mice per group) were immunized subcuta-
neously at the base of their tails with the formulation bearing150 g 
of appropriate antigen.
In vivo assessment of DC maturation by flow cytometry
Spleens were collected and placed in complete RPMI media [RPMI, 
Gibco, 10% FBS, penicillin/streptomycin (100 U/ml), 0.4 mM 
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suspension from spleens was obtained by passing the tissue through 
a 70-m nylon strainer (Corning), and erythrocytes were eliminated 
with ACK Lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM 
EDTA). Single cells were washed and resuspend in 5 ml of complete 
RPMI (Gibco). Two-fifth of the spleen sample was used for the 
staining. Prior antibody staining mouse FC receptors were blocked 
using TruStain FCX (BioLegend, San Diego, California) at 1:200 di-
lution in FACS buffer (PBS, 2% FBS) for 15 min on ice. Surface 
markers were stained for 40 min using combinations of labeled 
monoclonal antibodies diluted in PBS: CD45.2-PE-dazzle (clone 104), 
CD11c-PE-Cy7 (clone N418), MHC-II-BV421 (clone M5/114.15.2), 
F4/80-APC-Cy7 (clone CI-A3–1), CD40-FITC (3/23), CD80-PE 
(clone 16-10A1), rat IgG2a,  isotype Ctrl-FITC (clone RTK2758), 
Armenian hamster IgG isotype Ctrl-PE (clone HTK888), rat IgG2b, 
and  isotype Ctrl-APC (RTK4530) (BioLegend). For Foxp3 intra-
cellular staining, the Foxp3 staining buffer set kit (eBioscience) was 
used following the manufacturer’s recommendations. Before analysis, 
samples were washed twice with permeabilization buffer. All sam-
ples were resuspended in 200 l of PBS before analysis, and 10-l 
Beckman Coulter count beads were added for absolute number 
quantification. Stained samples were analyzed on Flow Cytometry BD 
LSRFortessa. Measurements of median were used to calculate the mean 
fluorescence intensity of cell populations using FlowJo software.
ELISpot assay
Splenocytes from immunized animals were isolated at 14 days fol-
lowing the last immunization and assessed by ELISpot for IFN-, 
IL-4, and IL-17A production. Multiscreen plates, 96 wells (MAHA, 
MAIP, or MSIP, Millipore), were coated overnight at 4°C with anti- 
mouse IFN- (5 g/ml; AN18, Mabtech), anti-mouse IL-4 (5 g/ml; 
BVD4-1d11, BD Biosciences), or IL-17A (5 g/ml; Mabtech). Plates 
were washed five times with PBS and blocked with RPMI 1640 
(Gibco, Life technologies) containing 10% FBS [supplemented with 
penicillin (100 U/ml), streptomycin (100 g/ml), 2 mM l-glutamine, 
1 M Hepes, and 0.1 mM 2-mercaptoethanol] for 2 hours at 37°C. 
Splenocytes were added at a final concentration of 0.5 × 106 per well 
and coincubated with recall antigens (1, 5, and PADRE conjugated 
to an unrelated peptide at a final concentration of 25 g/ml) in com-
plete media for 12 to 16 hours at 37°C (IFN-), 20 to 24 hours (IL-4), 
and 40 to 48 hours (IL-17A). Media alone and positive control con-
canavalin A (1 g/ml final) wells were also added. Following incu-
bation, plates were washed with PBS, and anti-mouse IFN-–biotin 
(1 g/ml; R4-6A2, Mabtech), anti-mouse IL-4–biotin (BVD6-24G2, 
Mabtech or BD Biosciences), or anti-mouse IL-17A–biotin (BD 
Biosciences) in 0.5% FBS/PBS was added for 2 hours at room tem-
perature (IFN- and IL-17A) or overnight at 4°C for IL-4. Plates 
were washed, and streptavidin-ALP (1 g/ml) or ExtrAvidin-ALP 
(1 g/ml) in 0.5% FBS/PBS was added for a further 1.5 hours at room 
temperature. Plates were given a final wash with PBS followed by 
reverse osmosis water, and spots were developed using an AP colo-
rimetric kit (Bio-Rad). Once plates were dry, spots were counted 
using an AID ELISpot Reader system.
Antibody titer evaluation by ELISA
The J8-specific IgG in murine serum/saliva and J8-specific IgA in 
murine saliva collected from the C57BL/6 mice after each immuni-
zation were measured by ELISA. Polycarbonate plates were coated 
with J8 peptide (pH 9.6, 0.5 mg/ml in a carbonate coating buffer) 
with amount of 100 l per well, and incubated at 4°C overnight. 
Then, after washing the plates five times with PBS–Tween 20 buffer, 
150 l of 5% skim milk PBS–Tween 20 was added. After incubation 
at 37°C for 2 hours, plates were washed again. Sera samples (200 l 
of 1:100 dilution) or saliva samples (100 l of 1:2 dilution) were 
added to the plate followed by serial dilution down the plate in 0.5% 
skim milk PBS–Tween 20 buffer. All plates were incubated for 
1.5 hours in a 37°C incubator. The plates were washed five times, 
and 100 l per well of 1:3000 diluted peroxidase-conjugated goat 
anti-mouse IgG (in 0.5% skim milk PBS–Tween 20) or 50 l per 
well of 1:1000 diluted goat anti-mouse IgA (in 0.5% skim milk PBS–
Tween 20) was added; the plates were incubated for 1.5 hours at 
37°C. After incubation, plates were washed again, and 100 l per 
well of o-phenylenediamine dihydrochloride (OPD) substrate was 
added. The plates were incubated for 30 min in a dark environment 
at room temperature, and then the absorbance of stained J8-specific 
IgG or IgA was measured at  450 nm.
Bactericidal assessment
An opsonization assay was performed with serum collected from 
immunized mice to evaluate the bactericidal efficacy. Clinical iso-
lates were provided from Princess Alexandra Hospital that includes 
(i) ACM-2002 (Royal Brisbane Hospital, human abscess–lymph gland), 
(ii) ACM-5199 (ATCC 12344, NCIB 11841, scarlet fever), (iii) ACM- 
5203 (ATCC 19615, pharynx of child followed by episode of sore 
throat), (iv) GC2 203 (wound swab), (v) D3840 (nasopharynx swabs), 
(vi) D2612 (nasopharynx swabs). The bacteria were prepared by 
streaking on THB agar supplemented with 5% yeast extract and in-
cubated (37°C, 24 hours). A single colony from the bacterium was 
transferred to THB (5 ml) supplemented with 5% yeast extract and 
incubated for 24 hours at 37°C to give approximately 4.6 × 106 colony- 
forming units (CFU)/ml. The culture was serially diluted to 10-2 in 
PBS, and an aliquot (10 l) was mixed with heat-inactivated sera (10 l) 
and horse blood (80 l). The inactivated sera were prepared by heat-
ing in a 50°C water bath for 30 min. The bacteria incubation was 
conducted in the presence of sera in a 96-well plate at 37°C for 3 hours. 
Ten microliters of this suspension was plated on Todd-Hewitt agar 
plates supplemented with 5% yeast extract and 5% horse blood. The 
plates were incubated at 37°C for 24 hours. The bacteria survival 
rate was analyzed on the basis of the CFU enumerated from the in-
cubated Todd-Hewitt agar plates. The assay was performed in trip-
licate from three independent cultures.
Cell lines and ELISA inflammatory cytokine detection
Immortalized wild-type C57BL/6 macrophages were grown in DMEM 
(Gibco) supplemented with 10% heat-inactivated FBS and 2 mM 
glutamine. 1 × 106 cells/ml were seeded in six-well plates, left to 
settle for an hour, and subsequently stimulated with LPS (100, 50, 
and 1 ng/ml), 1 (0.1 mg/ml), control (0.1 mg/ml), silica (250 g/ml; 
U.S. Silica), or left untreated. Cells were stimulated for either 4 or 6 hours 
and maintained at 37°C in a 5% CO2 incubator. For the detection of 
IL-1b and TNF, culture supernatants were harvested by washing 
with PBS and detached with Glutamax. Debris were pelleted at 201,000g, 
5 min, 4°C, and either 50 or 100 l of undiluted sample supernatant 
was used in a mouse IL-1b or TNF ELISA according to the manu-
facturer’s specifications.
Statistical analysis
GraphPad Prism 7 software (GraphPad Software Inc., California, USA) 
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fluorescence intensity was recorded. Two-way analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison test was ap-
plied during the statistical analysis, with P < 0.05 considered statis-
tically significant. The titer of the J8-specific IgG or IgA was described 
as the lowest dilution that offered an absorbance of greater than 3 SD 
above the mean absorbance of the negative control wells (wells coated 
with serum from mice immunized with PBS). A one-way ANOVA 
followed by Tukey’s post hoc test was applied to statistical analysis 
of the antibody titers and ELISpot, with P < 0.05 considered statistically 
significant. The opsonic activity of the antibody (anti-peptide) sera 
(% reduction in mean CFU) was calculated as [1 − (CFU in the pres-
ence of anti-peptide sera)/(mean CFU in the presence of PBS)] × 100. 
One-way ANOVA followed by Tukey’s post hoc test was applied for 
the opsonization statistical analysis, with P < 0.05 considered statis-
tically significant. The bacteria infection challenge evaluation of CFU 
was recorded and analyzed by one-way ANOVA followed by Tukey’s 
post hoc test, with P < 0.05 considered statistically significant.
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